Clear Filter

Jun 20, 2019

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 20, 2019 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $1.07 per share. 

Jun 12, 2019

New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arthritis Including Results on Clinical Remission at 48 Weeks Presented at EULAR

NORTH CHICAGO, Ill., June 12, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results from the Phase 3 clinical trials SELECT-EARLY and SELECT-COMPARE showing that patients receiving upadacitinib once-daily (15 mg or 30 mg, SELECT-EARLY; 15 mg plus methotrexate (MTX), SELECT-COMPARE) through 48 weeks continue to demonstrate improved signs and symptoms of rheumatoid arthritis, as measured by ACR20/50, and clinical remission based on Disease Activity Score 28 C-Reactive Protein (DAS28-CRP)<2.6.1,2 The studies evaluate upadacitinib, an investigational, once-daily JAK1-selective inhibitor, in patients with moderately to severely active rheumatoid arthritis.1,2 Additionally, data from an integrated safety analysis across five Phase 3 SELECT clinical trials show that treatment with upadacitinib in patients with moderately to severely active rheumatoid arthritis demonstrates a consistent safety profile.3

Jun 11, 2019

New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

NORTH CHICAGO, Ill., June 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new results showing a significant number of patients treated with SKYRIZI™ (risankizumab) experienced complete skin clearance at week 94.1 In the study, at week 28 patients who achieved a static Physician Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) were re-randomized to continue treatment with SKYRIZI or withdrawal.1 After 94 weeks of continuous treatment with SKYRIZI, 73 percent and 72 percent of these patients achieved a sPGA score of clear (sPGA 0) and a 100 percent improvement in the Psoriasis Area and Severity Index (PASI 100), respectively, compared to 2 percent of patients re-randomized to withdrawal (p<0.001).1 These two-year results (up to 104 weeks) from the Phase 3 IMMhance study, evaluating the efficacy and safety of SKYRIZI in adult patients with moderate to severe psoriasis, will be presented today at the 24th World Congress of Dermatology (WCD) in Milan.

Jun 10, 2019

AbbVie Employees to Help Underserved Communities in Sixth-Annual "Week of Possibilities"

NORTH CHICAGO, Ill., June 10, 2019 /PRNewswire/ -- AbbVie, a research-based global biopharmaceutical company, kicks off its sixth annual Week of Possibilities global employee volunteering program this week. Approximately 9,000 AbbVie employees will work with leading nonprofit groups, completing hands-on volunteer projects in underserved communities.

Jun 07, 2019

AbbVie to Present at the Goldman Sachs Global Healthcare Conference

NORTH CHICAGO, Ill., June 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Goldman Sachs 40th Annual Global Healthcare Conference on Wednesday, June 12, 2019. Michael Severino, vice chairman and president, will present at 10:00 a.m. Central time.

Jun 04, 2019

AbbVie Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 data from CLL14 study were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine

May 30, 2019

AbbVie Presents Results from Several Studies and Clinical Trials Investigating Medicines Across More than 15 Cancers at the 2019 ASCO and EHA Meetings

NORTH CHICAGO, Ill., May 30, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it will present more than 40 data updates across its oncology portfolio during the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on May 31-June 4, in Chicago, and the European Hematology Association (EHA) Annual Congress on June 13-16, in Amsterdam. The data presentations will span the company's investigational and approved oncology portfolio medicines in more than 15 different blood and solid tumor cancers.

May 17, 2019

AbbVie Provides Update on Depatuxizumab Mafodotin (Depatux-M), an Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer

NORTH CHICAGO, Ill., May 17, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the Phase 3 INTELLANCE-1 study of depatuxizumab mafodotin (Depatux-M, previously known as ABT-414) in patients with newly diagnosed glioblastoma (GBM), whose tumors have EGFR (epidermal growth factor receptor) amplification, demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis. An Independent Data Monitoring Committee (IDMC) recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with placebo when added to the standard regimen of radiation and temozolomide. No new safety findings were observed. Enrollment in all ongoing Depatux-M studies has been halted.

May 15, 2019

AbbVie Announces US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

NORTH CHICAGO, Ill., May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 The FDA granted Breakthrough Therapy designation for this combination therapy, and early submission of the data was provided under the Real-Time Oncology Review (RTOR) pilot program, which led to approval in just over two months, following submission of the complete application. 

May 14, 2019

AbbVie Resolves HUMIRA® (adalimumab) U.S. Patent Litigation with Boehringer Ingelheim

NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.S. HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI). Under the terms of the resolution, AbbVie will grant BI a non-exclusive license to its HUMIRA-related intellectual property in the United States. The U.S. license for BI will begin on July 1, 2023.  BI will pay royalties to AbbVie for licensing its HUMIRA patents and acknowledges the validity and enforceability of the licensed patents. AbbVie will make no payments of any form to BI.